key: cord-1043493-qtbv8bm4
authors: Kim, David D.; Silver, Madison C.; Kunst, Natalia; Cohen, Joshua T.; Ollendorf, Daniel A.; Neumann, Peter J.
title: Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018
date: 2020-07-22
journal: Pharmacoeconomics
DOI: 10.1007/s40273-020-00942-2
sha: 0fffe93c6beff3e0f5a47b14b81debc94898845e
doc_id: 1043493
cord_uid: qtbv8bm4

OBJECTIVE: Our objective was to examine perspective and costing approaches used in cost-effectiveness analyses (CEAs) and the distribution of reported incremental cost-effectiveness ratios (ICERs). METHODS: We analyzed the Tufts Medical Center’s CEA and Global Health CEA registries, containing 6907 cost-per-quality-adjusted-life-year (QALY) and 698 cost-per-disability-adjusted-life-year (DALY) studies published through 2018. We examined how often published CEAs included non-health consequences and their impact on ICERs. We also reviewed 45 country-specific guidelines to examine recommended analytic perspectives. RESULTS: Study authors often mis-specified or did not clearly state the perspective used. After re-classification by registry reviewers, a healthcare sector or payer perspective was most prevalent (74%). CEAs rarely included unrelated medical costs and impacts on non-healthcare sectors. The most common non-health consequence included was productivity loss in the cost-per-QALY studies (12%) and patient transportation in the cost-per-DALY studies (21%). Of 19,946 cost-per-QALY ratios, the median ICER was $US26,000/QALY (interquartile range [IQR] 2900–110,000), and 18% were cost saving and QALY increasing. Of 5572 cost-per-DALY ratios, the median ICER was $US430/DALY (IQR 67–3400), and 8% were cost saving and DALY averting. Based on 16 cost-per-QALY studies (2017–2018) reporting 68 ICERs from both the healthcare sector and societal perspectives, the median ICER from a societal perspective ($US22,710/QALY [IQR 11,991–49,603]) was more favorable than from a healthcare sector perspective ($US30,402/QALY [IQR 10,486–77,179]). Most governmental guidelines (67%) recommended either a healthcare sector or a payer perspective. CONCLUSION: Researchers should justify and be transparent about their choice of perspective and costing approaches. The use of the impact inventory and reporting of disaggregate outcomes can reduce inconsistencies and confusion. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s40273-020-00942-2) contains supplementary material, which is available to authorized users.

Practice guidelines for cost-effectiveness analysis (CEAs) emphasize the importance of the analytic perspective assumed in the analysis because it determines which costs and benefits are included [1] [2] [3] [4] . The perspective may reflect a patient, a specific payer (public or private), the entire healthcare sector, or all of society. The choice of perspective and included cost components may have a substantial impact on the cost-effectiveness of interventions and, consequently, policy and resource allocation decision making [5] [6] [7] .

Ideally, the relevant audience-i.e., the population "on whose behalf are decisions made"-influences the choice of perspective [8] . Practice guidelines that endorse a broader societal perspective argue that considering everyone affected and counting all benefits and costs, regardless of who gains or loses, can provide the basis for fair decisions in the

The analytic perspective assumed in cost-effectiveness analysis determines which costs and benefits are included. Despite its importance, study authors often mis-specified or did not clearly state the perspective used.

When a societal perspective was used, authors often did not apply it as broadly as intended. Only a few nonhealth consequences, such as productivity or transportation, were considered, whereas broader non-healthcare sector impacts were seldom examined.

The use of a healthcare payer or a healthcare sector perspective persists in most published studies and national guidelines because "relevant" non-health benefits and costs are often difficult to define and may depend on the context. The consistent use of the impact inventory and reporting of disaggregate outcomes can help reduce discrepancies across analyses capturing non-health consequences.

Although a few studies have documented variations in perspective used and costing approaches [11] [12] [13] , the number of published CEAs has increased substantially in recent years, and many countries have formally adopted a health technology assessment (HTA) process [14] . We sought to examine the use of perspective and costing approaches, including the use of multiple perspectives and the impact inventory, in published CEAs through 2018 and their impact on reported incremental cost-effectiveness ratios (ICERs). In addition, we reviewed 45 country-specific guidelines to examine recommended analytic perspectives in HTA.

In this paper, we avoid the widespread notions of "direct" and "indirect" costs as it is often difficult to differentiate between direct and indirect consequences of disease and its treatment. Also, a range of possible consequences could be deemed "direct" depending on the perspective of the analysis (e.g., all non-health consequences that influence public welfare can be considered "direct" from a societal perspective) [15] . Instead, we use the term "non-health consequence" to capture both medical and non-medical resources consumed. The non-health consequences include patient time, transportation costs, caregiver time, productivity, and other non-healthcare sector impacts on education, criminal justice, housing, and environment. Based on this categorization, we applied the following definition of analytic perspectives:

Healthcare payer: This perspective includes only those monetary costs (e.g., treatment costs and other health service resource use associated with disease management) incurred by a (typically third party) healthcare payer (e.g., Medicare/ Medicaid, British national health service, a health maintenance organization, etc.).

Healthcare sector: This perspective is similar to the healthcare payer perspective but accounts for all monetary costs of healthcare, regardless of who bears the cost. A key distinction between the healthcare sector and healthcare payer perspectives is that the healthcare sector perspective includes patients' out-of-pocket costs.

Limited societal: This perspective accounts for cost components beyond those captured by the healthcare sector perspective, including patient time, patient transportation, unpaid caregiver time, and productivity loss. It excludes spillover impacts affecting sectors other than healthcare, such as education. public interest [1, 8, 9] . A societal perspective means that all resources (both health related and not) associated with the intervention should be identified, measured, and valued. Some guidelines, such as the Original Panel on Cost-Effectiveness in Health and Medicine in 1996 [8] , have suggested the use of a societal perspective as a reference case analysis to encourage comparability and consistency of the analytic perspective across CEAs.

However, since publication of the Original Panel's guideline, awareness of challenges in how to implement a "societal" perspective has grown. Recognizing practical difficulties and the revealed preferences of some policy makers to support narrower perspectives, the Second Panel on Cost-Effectiveness in Health and Medicine revised the original guidelines in 2016. A major change in the Second Panel's guideline includes two reference case analyses, from both a healthcare sector and a societal perspective [10] . Along with the recommendation, the Second Panel advises the use of an "impact inventory" to help standardize practice and reduce confusion. The impact inventory is a structured table listing an intervention's health and non-health consequences, including those falling outside the formal healthcare sector. Although the Second Panel's updated recommendation for the inclusion of an impact inventory was published in 2016, to our knowledge, its impact on practice has not yet been evaluated.

Understanding past and current practices can shed light on the gap between guideline recommendations and actual behavior and provide future directions for improvement.

Societal: A societal perspective is broader than the limited societal perspective. It represents the overall public interest by including all resources that could be used for other purposes. The analysis accounts for cost impacts affecting at least one of these other sectors, such as the environment, education, or the justice system.

Not stated/could not be determined: This designation indicates that the authors did not provide sufficient information for us to determine the type of costs or benefits included in the analysis.

We analyzed data from the Tufts Medical Center's CEA Registry (a database of cost-per-quality-adjusted-life-year [QALY] studies; available at www.ceare gistr y.org) and the Global Health CEA (GHCEA) registry (an open-access database of cost-per-disability-adjusted-life-year [DALY] studies; available at www.ghcea regis try.org). Both registries contain information from English-language, PubMedindexed original CEAs (i.e., excluding reviews, editorials, or methodological articles) from 1974 through 2018, which report at least one cost-per-QALY gained or cost-per-DALY averted ratio, including interventions with cost-saving (i.e., dominant) or dominated ratios. We identified 6907 cost-per-QALY and 698 cost-per-DALY studies, reporting 19,946 and 5572 intervention-specific ICERs, respectively. All of the ratios available in the registries were converted to $US, year 2018 values based on currency conversions [16] and inflation adjustments using the consumer price index [17] .

Both registries applied structured and standardized data collection processes to ensure the consistency and quality of the data. Methodological details are available elsewhere [18, 19] , including the registry website, but we briefly summarized the process. After an initial literature search, at least two registry reviewers independently conduct abstract screening to determine eligibility for the full review. Among articles selected for the full review, each reviewer used a prespecified data collection form to extract information on a wide range of variables, including author affiliation, study country, study sponsorship, intervention, comparator(s), target population, perspective, time horizon, discounting rate, cost-effectiveness ratios, etc. [20] . Throughout the process, the reviewers engaged in a consensus discussion to address any discrepancies before moving onto the next step.

We first investigated the use of perspective and its changes over time among cost-per-QALY and cost-per-DALY studies, including any discrepancies between the perspective reported by the study authors and the perspective used in the analysis, as determined by our registry reviewers. Registry reviewers extracted information pertaining to the analytic perspective stated by authors, and two trained reviewers reclassified the perspective based on their assessment of the presented analysis and cost components included. For example, if an author stated that the analysis used the societal perspective but did not describe the inclusion in the analysis of any spillover costs affecting other sectors (e.g., education, housing, judicial), then the reviewer designated the actual perspective as limited societal. For comparative analyses, we excluded papers for which the perspective was not stated/could not be determined and aggregated the remaining papers into either societal/limited societal or healthcare sector/payer.

We also examined how often published CEAs included cost components beyond those traditionally included in an analysis from a healthcare sector perspective. Due to changes in the data collection methodology for the CEA registry [20], we were only able to obtain information on specific cost components included in cost-per-QALY articles published since 2013 (N = 2839 of 6907). On the other hand, we retained that information for all 698 cost-per-DALY studies in the GHCEA registry.

We compared cost components included in cost-per-QALY versus cost-per-DALY studies and then investigated how the choice of the analytic perspective influences the reported ICERs across different intervention types and study sponsors. To further examine the association between the inclusion of cost components and reported ICER values, we analyzed a subset of cost-per-QALY studies (those published in 2017-2018) and cost-per-DALY studies that reported cost-effectiveness ratios from both a healthcare sector and a societal perspective. Using ratios drawn from the same study makes it possible to isolate the impact of altering the perspective while holding all other aspects of the CEA unchanged. Additionally, we examined the inclusion of the impact inventory, which is recommended by the Second Panel.

We also reviewed 45 national, country-specific guidelines governing economic evaluation or HTA to examine differences in recommended analytic perspectives across countries. We identified the national guidelines from a literature search, online databases, and published reviews of HTA guidelines [21] [22] [23] [24] [25] [26] [27] . We classified the recommended perspectives based on the cost components recommended for inclusion and from the guideline perspective statements. In some cases, although the guidelines recommended a healthcare sector perspective, they only accounted for healthcare payer costs, and we reclassified them as describing a healthcare payer perspective. Additionally, among the top five countries with most CEAs produced (the USA, the UK, Canada, Netherlands, and Australia), we examined differences in the proportions using the societal perspective and its consistency with the national guidelines.

Study authors often mis-specified the perspective used, and 20% of CEAs (both cost-per-QALY and cost-per-DALY studies) did not clearly state the study perspective. After the registry reviewers reclassified the study perspective based on types of costs or benefits evaluated, the study perspective was unable to be determined in only 7% of CEAs. Based on the perspective as determined by registry reviewers, published CEAs most often used a healthcare sector perspective (75% of cost-per-QALY studies and 65% of cost-per-DALY studies). Our data indicate that cost-per-QALY study authors reported a societal/limited societal perspective more frequently than it was actually used, as determined by registry reviewers. In contrast, cost-per-DALY study authors tended to underreport the use of a societal/limited societal perspective by mis-specifying it as a healthcare sector perspective (Table 1) . While the use of the healthcare perspective in cost-per-QALY studies has increased over the past decade ( Fig. 1) , the perspective used in cost-per-DALY studies has not changed significantly over time (Electronic Supplementary Material [ESM] A: Table A and Fig. A) .

Although most studies included immediate medical costs associated with the intervention, less than half included future medical costs related to the intervention (Fig. 2) . While future unrelated medical cost data were not available in the cost-per-QALY registry, cost-per-DALY studies rarely included future unrelated medical costs (i.e., background medical costs of treating conditions in added years of life). Cost-per-DALY studies were more likely to include at least one cost component outside of the healthcare sector (36 vs. 10% cost-per-QALY studies). The most commonly included non-health consequence was productivity (12%) in cost-per-QALY studies and patient transportation (21%) in cost-per-DALY studies. Published CEAs rarely examined impacts affecting other non-healthcare sectors, such as criminal justice, education, and housing (2% among cost-per-QALY studies, and 5% among cost-per-DALY studies). Overall, among cost-per-QALY ratios calculated from a healthcare sector perspective (76%), the median ICER was $US25,000/QALY (IQR 3100-100,000); the corresponding median ICER among the ratios calculated from a societal . B ).

In the cost-per-QALY literature, drug and device industry-sponsored studies consistently reported lower median ICERs than non-industry-sponsored studies from both perspectives (i.e., $US18,000 vs. 31,000/QALY from a healthcare sector perspective and $US27,000 vs. 36,000/ QALY from a societal perspective). We found a paucity of cost-per-DALY ratios from industry-sponsored studies (4%, n = 197), and none of the industry-sponsored cost-per-DALY ratios reported that the interventions were "dominated" (i.e., less effective and more costly than its comparator; ESM A: Tables C and D).

For the years 2017-2018, we identified 11 cost-per-QALY studies (1.0%) that included the impact inventory table (we did not collect this information among cost-per-DALY studies). Nine of 11 studies came from the USA (n = 5) or the UK (n = 4), from which at least one member of the Second Panel came. Two other studies were from Ireland and Switzerland. We found that 16 cost-per-QALY studies (1.4%) reported a total of 68 cost-per-QALY ratios from a healthcare sector and a societal perspective (34 ratios from each perspective), and five cost-per-DALY studies (0.7%) reported a total of 72 cost-per-DALY ratios (36 ratios from each perspective). Seven of 16 cost-per-QALY studies reported one ratio from each perspective [28] [29] [30] [31] [32] [33] [34] , whereas two studies reported five and six intervention-specific ratios from each perspective, respectively [35, 36] . Four of five cost-per-DALY studies reported one or two ratios from each perspective [37] [38] [39] [40] , and one multicountry study reported 31 ratios from each perspective [41] .

The studies that reported ratios from both perspectives had lower ( Due to expensive treatments relative to the non-health benefits, three studies that included specific non-health consequences, such as productivity or caregiver cost, reported higher median ICERs than those from 16 studies that used a healthcare sector perspective (Fig. 3) . However, within these studies [31, 42, 43] , the median ICER from a societal perspective was substantially lower than that from a healthcare perspective ($US42,745 vs. 123,514/QALY, respectively).

Most government guidelines (67%) recommend either a healthcare payer or healthcare sector perspective as the reference perspective (Fig. 4 and Our country-specific analysis showed that the proportion of cost-per-QALY studies for the Netherlands from a societal perspective was 49% (232 of 476), almost three times higher than the average among the entire cost-per-QALY literature (16.9%). Among the top five CEA-producing countries, the Netherlands was the only one that recommended a societal perspective, whereas the UK, Canada, and Australia recommended a narrower (national healthcare payer or healthcare sector) perspective. Only 14% (99 of 519) and 10% (118 of 1225) of Australia-and UK-based cost-per-QALY studies were conducted from a societal perspective, respectively (ESM A: Fig. C ).

Using an updated database of published CEA, we found that key study attributes-including perspective and cost components considered-varied substantially across types of evaluation and setting. In particular, we found a considerable discrepancy between the author's stated perspective and our reviewers' judgments about the perspective used. It appears that some researchers are unclear on what cost components should be included in a CEA conducted from a societal perspective. When analysts did use a societal perspective, they often did not apply it as broadly as the Second Panel and other experts intended. Only a few non-health consequences related to the intervention-for example, productivity or transportation-were considered, whereas broader non-healthcare sector impacts-for example, those affecting the criminal justice system or education-were seldom examined.

We also found substantial variation among reported cost-effectiveness ratios by study characteristics and costing approaches. Specifically, the analysis of the subset of cost-per-QALY and cost-per-DALY studies that included multiple perspectives found that the inclusion of broader non-health consequences generally resulted in lower (more favorable) cost-effectiveness ratios. For example, pharmacotherapy for patients with alcohol use disorder becomes more cost-effective when improved outcomes that go beyond the healthcare sector, such as improved productivity or reduced alcohol-related motor vehicle accidents, are accounted for [44] . However, this may not always be the case as the inclusion of non-health consequences can sometimes result in less favorable cost-effectiveness ratios (e.g., the early discharge of patients from hospitals can lead to higher informal caregiver costs and thus less favorable cost effectiveness).

However, the use of a healthcare payer or a healthcare sector perspective persists in most published studies and national guidelines. By taking a narrower perspective, some aspects of societal value elements can be omitted, and, possibly, decisions based on such analysis may not optimize overall welfare. In practice, as our analysis indicated inconsistent and incomplete inclusion of non-health consequences across CEAs, normative questions about how to define "relevant" non-health benefits and costs are often difficult to answer and may depend on the context. As Culyer et al. [21] noted, Fig. 3 Incremental cost-effectiveness ratios by the inclusion of non-health components. Note: The size of the circle represents the volume of included studies for each perspective non-health components. For studies that included each cost component, the center of the circle denotes the median incremental cost-effectiveness ratios (ICER) while the lines extend to the 25th and 75th percentiles, the inter-quartile range (IQR). Due to the wide IQR of some ICERs, Lines extending to the x-axis represent interventions that were cost-saving at the 25th percentile. None of the cost-per-DALY studies included productivity or non-healthcare sector costs "the perspective will usually be context-dependent, with the context determining the appropriate perspective."

Without knowing the context of the decision being made, researchers may continue to struggle to implement a broader societal perspective. A step forward would be to increase the use of an impact inventory, as this can ensure that all of the standardized consequences of interventions, including those falling outside the formal healthcare sector, are considered regularly and comprehensively [14] . Despite a low uptake of the impact inventory in the first 2 years since the Second Panel's recommendation, the trend is upward (0.7% in 2017, 1.4% in 2018, and 2.7% in 2019 [based on partial 2019 data]), and the Institute for Clinical and Economic Review included it as part of its evidence assessments [45] . Widespread use of the impact inventory would provide the relevant information in a comprehensive, consistent, and transparent manner to guide decision makers with different preferences with regard to what should be included in a technology assessment. For example, a recent commentary provided a modified impact inventory to list a set of key health and social consequences to consider when evaluating the cost effectiveness of policy responses for coronavirus disease 2019 (COVID-19) [46] .

Although relevant non-health consequences can be identified, how to measure and value these consequences poses challenges. Researchers have pointed to a few methodological questions involved in costing, such as whether estimated costs should explicitly account for lost productivity from morbidity, whether such effects are already captured in measuring QALYs, or whether analysts should capture unrelated downstream costs (e.g., future unrelated medical costs and non-health consumptions during the extended life-years) [47] [48] [49] [50] [51] [52] . In addition, analytic difficulties-including the lack of available data (e.g., on informal caregiver time or nonlabor market productivity) [53] -have impeded the widespread implementation of a societal perspective in practice. Developing a country-specific cost catalog for non-health consequences (e.g., criminal justice system resource use, hourly wages, and annual non-health consumption) can help standardize and promote CEAs from a societal perspective [54] .

Our study documented the lack of inclusion of informal caregiver time (i.e., spillover costs). However, an important health consequence-spillover health effects on family members and informal caregivers of patients, which might be considered irrespective of the perspective chosen-is also often omitted [55] . For example, CEAs of interventions for Alzheimer's disease or a pediatric population are more likely to include both types of spillover effects than the overall literature, but spillover health effects were considered substantially less often than spillover costs [56, 57] . Recent advances in methodology and applications for measuring and valuing spillover effects have provided a set of useful resources for analysts to incorporate the spillover effects into CEAs from both a healthcare sector and a societal perspective [58] .

Our analyses have some limitations. The CEA and GHCEA registries catalog only English-language, published cost-per-QALY-gained and cost-per-DALY-averted studies and do not capture the gray literature (e.g., HTA reports that may not be disseminated in regularly published, indexed journals) or other databases. Still, one study found that our registry databases reached 95% of published cost-per-QALY or cost-per-DALY literature [59] . In addition, the classification of the analytic perspective and costing approach involves reviewer judgment based on the available information (e.g., whether the stated perspective was matched with cost components presented). Despite our efforts to reduce discrepancies by holding consensus meetings with at least two reviewers, others may render different judgments.

In the analysis of the national HTA guidelines, although we performed a detailed scoping literature search to identify the most recent country-specific recommendations, our search may have failed to identify updated versions of some of the recommendations. In addition, some of the guidelines provided scarce information about the recommended perspective. In these cases, we either used the perspective stated in the guideline or categorized the perspective based on the limited information provided.

The choice of analytic perspective and cost components to include in a health economic evaluation can have an important impact on value assessment. Researchers and analysts should be transparent about their choices. Revised guidelines by the Second Panel, including the use of the impact inventory and reporting of disaggregated outcomes, can help reduce inconsistencies across analyses and the attendant confusion.

Author Contributions DDK and PJN conceived and designed the study, and PJN secured funding for this study. DDK, MCS, and NK were responsible for conducting empirical analyses. DDK wrote the initial manuscript and acted as an overall guarantor for the overall content of this article. All authors elaborated on, discussed, and approved the final version of the manuscript submitted for publication.

Funding This work was supported by the Center for Enhanced Value Assessment at the Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, funded by the PhRMA Foundation Center of Excellence in Value Assessment Award. The development and maintenance of the GHCEA registry is supported by the Bill and Melinda Gates Foundation, grant number OPP1171680. The funders had no role in study design, data collection, analysis or interpretation, preparation, review, or approval of the manuscript.

The data used in our analysis are publicly accessible through Tufts Medical Center's CEA registry (restricted public access), the GHCEA registry (open access), and country-specific guidelines (available online). The specific analytic datasets are available from the corresponding author upon reasonable request.

Conflicts of interest DDK, MCS, JTC, DAO, and PJN are employees of the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, which maintains the CEA Registry and the GH-CEA registry used as data sources for this study. The CEA registry is supported by subscription revenue from pharmaceutical and device companies, academic institutions, and government agencies. The GH-CEA registry is supported by a grant from the Bill and Melinda Gates Foundation. NK was funded by the Research Council of Norway and LINK Medical Research (grant numbers 276146 and 304034) and has received personal fees for speaking from Thermo Fisher Scientific, outside of the submitted work. JTC has received grants for work conducted on behalf of Amgen, Biogen, and Janssen Pharmaceuticals and has lectured on the use of simulation for Pfizer. JTC has also consulted for AbbVie, Precision Health Economics, Sage Therapeutics, and Sarepta, outside of the submitted work. PJN has held one-time roles on the advisory boards on health economics topics for Avexis, AbbVie, Research Triangle Institute, Merck, Genentech, Bluebird Bio, and Novo Nordisk. PJN serves on the advisory board for the Congressional Budget Office and has consulted for Precision Health Economics, outside of the submitted work.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by-nc/4.0/.

Methods for the economic evaluation of health care programmes

An overview of value, perspective, and decision context-A health economics D. D. Kim et al. approach: an ISPOR special task force report

The International decision support initiative reference case for economic evaluation: an aid to thought

Cost-effectiveness in health and medicine

Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension

Do productivity costs matter? The impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders

Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies

Cost-effectiveness in health and medicine

Is the societal perspective in cost-effectiveness analysis useful for decision makers?

Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine

Costing and perspective in published cost-effectiveness analysis

Cost-effectiveness analysis: can we reduce variability in costing methods?

Measuring costs in cost-utility analyses. Variations in the literature

Mapping of HTA methodologies in EU and Norway

Estimating costs and valuations of non-health benefits in cost-effectiveness analysis

Historical Consumer Price Index for All Urban Consumers (CPI-U)

A systematic review of cost-effectiveness studies reporting cost-per-DALY averted

The changing face of the cost-utility literature

Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?

Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study

Pharmacoeconomic Guidelines Around The World

Methods for health economic evaluations : A guideline based on current practices in Europe

Health Intervention and Technology Assessment Program (HITAP). the Guide to Health Economic Analysis and Research (GEAR)

What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?

Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries

Cost-effectiveness of craniotomy for epidural hematomas at a major government hospital in Cambodia

Allocating provider resources to diagnose and treat restless legs syndrome: a costutility analysis

Public health impact and cost effectiveness of routine childhood vaccination for hepatitis a in Jordan: a dynamic model approach

A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America

Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour

Cost-effectiveness analysis of intensity modulated radiation therapy versus proton therapy for oropharyngeal squamous cell carcinoma

Cost-effectiveness of raising alcohol excise taxes to reduce the injury burden of road traffic crashes

Cost-effectiveness of a potential group B streptococcal vaccine for pregnant women in the United States

Costeffectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy

Cost-effectiveness of weight watchers and the lighten up to a healthy lifestyle program

Economic analysis for evidence-based policymaking on a national immunization program: a case of rotavirus vaccine in Thailand

Cost-effectiveness of rotavirus vaccination in Kenya and Uganda

Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh

Cost-effectiveness of dengue vaccination in ten endemic countries. Vaccine

The cost-effectiveness of surgical fixation of distal radial fractures: a computer modelbased evaluation of three operative modalities

Cost-effectiveness analysis of patient selftesting therapy of oral anticoagulation

Worked Example 1: the cost-effectiveness of treatment for individuals with alcohol use disorders: a reference case analysis

Institute for Clinical and Economic Review. 2020-2023 Value Assessment Framework2020

Analyzing the cost effectiveness of policy responses for COVID-19: the importance of capturing social consequences

Inconsistencies in the "societal perspective" on costs of the panel on cost-effectiveness in health and medicine

Productivity costs in cost-effectiveness analysis: numerator or denominator: a further discussion

Accounting for future costs in medical cost-effectiveness analysis

Cost recommendations in the second edition of costeffectiveness in health and medicine: a review

Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ

Completing costs: patients' time

Quantifying family spillover effects in economic evaluations: measurement and valuation of informal care time

Future directions for cost-effectiveness analyses in health and medicine

The inclusion of spillover effects in economic evaluations: not an optional extra

Family and caregiver spillover effects in costutility analyses of Alzheimer's disease interventions

Family spillover effects in pediatric cost-utility analyses

Advances in methods and novel applications for measuring family spillover effects of illness

Growth and capacity for cost-effectiveness analysis in Africa. Health Econ